Thiazolidinediones Inhibit Ovarian Cancer Cell Growth
Author Information
Author(s): Al-Alem Linah, Southard R. Chase, Kilgore Michael W., Curry Thomas E., Agoulnik Irina
Primary Institution: University of Kentucky College of Medicine
Hypothesis
Do thiazolidinediones (TZDs) affect ovarian cancer cell proliferation in a PPARγ dependent or independent manner?
Conclusion
CGZ and TGZ decrease ovarian cancer cell proliferation through a mechanism that is independent of PPARγ.
Supporting Evidence
- Treatment with CGZ decreased proliferation by 80% in Ovcar3 cells.
- TGZ caused a 65% decrease in cell proliferation.
- Rosi and Pio had no effect on cell proliferation.
- CGZ and TGZ increased apoptosis after 4 hours of treatment.
Takeaway
Some medicines called TZDs can help stop ovarian cancer cells from growing, and they do this without needing a specific protein called PPARγ.
Methodology
The study used ovarian cancer cell lines and treated them with different TZDs to measure cell proliferation and PPARγ activity.
Limitations
The study primarily focused on in vitro cell lines, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website